<DOC>
	<DOCNO>NCT02862743</DOCNO>
	<brief_summary>Analysis somatic mutation tumor currently indicate daily practice metastatic melanoma . Actually , research limit mutation three biomarkers validate l'Institut National du CAncer ( INCA ) : BRAF , NRAS CKIT . Moreover , case require invasive biopsy . In context , molecular characterization tumor material flow ( circulate tumor DNA / circulate tumor cell ) could afford benefit patient best condition current targeted therapy future .</brief_summary>
	<brief_title>Molecular Characterization Advanced Stage Melanoma Blood Sampling</brief_title>
	<detailed_description>The main objective study define diagnostic sensitivity panel biomarker circulate tumor DNA peripheral blood . The secondary objective study : - Study concordance mutation circulate tumor DNA mutation tumor tissue - Study association mutational profile clinical histological feature melanoma . - Study prognostic impact survival identify genetic profile circulate tumor DNA</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>patient melanoma confirm histologically patient metastatic melanoma ( stage III unresectable stage IV ) patient consent participate study patient enrol national healthcare insurance program patient old 18 year Metastatic tumor whose origin doubtful ( uncertain melanoma )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>